Simon Pacey

6.5k citations

69 papers · 3.9k indexed · 1 hit paper · h-index 20

Impact in

Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
Oncology top 2%
- Pancreatic and Hepatic Oncology Research
- Cancer Cells and Metastasis

Papers in ⓘ

Oncology 32
- Cancer Immunotherapy and Biomarkers 6
Cancer Research 13
- Cancer Genomics and Diagnostics 7

Co-authors: Javier García-Corbacho (5 shared papers)Richard D. Baird (7 shared papers)Florent Moulière (2 shared papers)Nitzan Rosenfeld (2 shared papers)James D. Brenton (1 shared paper)Carlos Caldas (2 shared papers)Jonathan C. M. Wan (1 shared paper)Charles Massie (2 shared papers)
Journals: Journal of Clinical Oncology (25 papers)Clinical Cancer Research (6 papers)Annals of Oncology (6 papers)Molecular Cancer Therapeutics (4 papers)Cancer Research (3 papers)
Partner nations: United Kingdom United States France

In The Last Decade

Simon Pacey

66 papers receiving 3.9k citations

Hit Papers

align trajectories log scale

Liquid biopsies come of age: towards implementation of circulating tumour DNA 2017 · 1.8k citations

Peers

Countries citing papers authored by Simon Pacey

Since Specialization

Citations

This map shows the geographic impact of Simon Pacey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Pacey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Pacey more than expected).

Fields of papers citing papers by Simon Pacey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Pacey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Pacey. The network helps show where Simon Pacey may publish in the future.

Co-authors

The 25 scholars most cited alongside Simon Pacey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Simon Pacey Line = papers co-authored together Simon Pacey links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Liquid biopsies come of age: towards implementation of circulating tumour DNA Nature reviews. Cancer ·Jonathan C. M. Wan, Charles Massie, Javier García-Corbacho, Florent Moulière, James D. Brenton, Carlos Caldas, Simon Pacey, Richard D. Baird, Nitzan Rosenfeld Hit paper breakdown →	2017	1766
2	Phase I Pharmacokinetic and Pharmacodynamic Study of 17-Allylamino, 17-Demethoxygeldanamycin in Patients With Advanced Malignancies Journal of Clinical Oncology ·Udai Banerji, Anne O’Donnell, Michelle Scurr, Simon Pacey, Sarah Stapleton, Yasmin J. Asad, Laura K. Simmons, Alison Maloney, Florence I. Raynaud, Maeli Campbell, Michael I. Walton, Sunil R. Lakhani, Stanley B. Kaye, Paul Workman, Ian Judson	2005	377
3	Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer The Lancet Oncology ·Chee-Seng Tan, David Gilligan, Simon Pacey	2015	315
4	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers Clinical Cancer Research ·Ruth Plummer, Gerhardt Attard, Simon Pacey, Louise Li, Albiruni R. Abdul Razak, Rebecca M. Perrett, Mary Barrett, Ian Judson, Stan B. Kaye, Norma Lynn Fox, Wendy Halpern, A. Corey, Hilary Calvert, Johann S. de Bono	2007	198
5	A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors Clinical Cancer Research ·Simon Pacey, Richard H. Wilson, Mike Walton, Martin Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik‐Tobias Arkenau, Javier Moreno‐Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johann S. de Bono, Florence I. Raynaud, Paul Workman, Ian Judson	2011	154
6	A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma Investigational New Drugs ·Simon Pacey, Martin Gore, David Chao, Udai Banerji, James Larkin, Sarah Sarker, Karen Owen, Yasmin J. Asad, Florence I. Raynaud, Mike Walton, Ian Judson, Paul Workman, Tim Eisen	2010	103
7	Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors Clinical Cancer Research ·Johann S. de Bono, Rebecca Kristeleit, Anthony W. Tolcher, Peter C.C. Fong, Simon Pacey, Vasilios Karavasilis, Monica Mita, Heather Shaw, Paul Workman, Stan B. Kaye, Eric K. Rowinsky, Wynne Aherne, Peter Atadja, Jeffrey W. Scott, Amita Patnaik	2008	97
8	Acquired Resistance to 17-Allylamino-17-Demethoxygeldanamycin (17-AAG, Tanespimycin) in Glioblastoma Cells Cancer Research ·Nathalie Gaspar, Swee Y. Sharp, Simon Pacey, Chris Jones, Michael I. Walton, Gilles Vassal, Suzanne A. Eccles, Andrew D.J. Pearson, Paul Workman	2009	92
9	Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit. Journal of Clinical Oncology ·I. Grant McQuaker, A Hunter, Simon Pacey, A. P. Haynes, Atif Iqbal, NH Russell	1997	91
10	Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers Journal of Clinical Oncology ·Emma Beddowes, James Spicer, Pui Ying Chan, Ramsay S. Khadeir, Javier Garciá Corbacho, Dimitra Repana, Jeremy Steele, Peter Schmid, Teresa Szyszko, Gary Cook, Monica Diaz, Xiaoxing Feng, Amanda Johnston, J. A. Thomson, Michael Sheaff, Bor-Wen Wu, John S. Bomalaski, Simon Pacey, Peter W. Szlosarek	2017	89
11	Hsp90 Inhibitors in the Clinic Handbook of experimental pharmacology ·Simon Pacey, U. Banerj, Ian Judson, Paul Workman	2005	76
12	Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations Clinical Cancer Research ·Lisa Zimmer, Fabrice Barlési, Maria Martinez‐García, Véronique Dièras, Jan H.M. Schellens, Jean‐Philippe Spano, Mark R. Middleton, Emiliano Calvo, L. Paz-Ares, James Larkin, Simon Pacey, Miro Venturi, Françoise Kraeber‐Bodéré, Jean Tessier, Wilfried Eberhardt, Michel Pâques, Ernesto Guarin, Valérie Méresse, Jean‐Charles Soria	2014	59
13	Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA Genome Research ·Irena Hudecova, Christopher G. Smith, Robert Hänsel‐Hertsch, Chandra Sekhar Reddy Chilamakuri, James A. Morris, Aadhitthya Vijayaraghavan, Katrin Heider, Dineika Chandrananda, Wendy N. Cooper, Davina Gale, Javier García-Corbacho, Simon Pacey, Richard D. Baird, Nitzan Rosenfeld, Florent Moulière	2021	58
14	Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of the Combination of Sorafenib and Tanespimycin Clinical Cancer Research ·Ulka N. Vaishampayan, Angelika M. Burger, Edward A. Sausville, Lance K. Heilbrun, Jing Li, M. Naomi Horiba, Merrill J. Egorin, Percy Ivy, Simon Pacey, Patricia LoRusso	2010	51
15	Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial Investigational New Drugs ·Simon Pacey, Mark J. Ratain, Keith T. Flaherty, Stanley B. Kaye, Lisa Cupit, Eric K. Rowinsky, Chenghua Xia, Peter J. O’Dwyer, Ian Judson	2009	40
16	A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo Autophagy ·Liam D. Cassidy, Andrew Young, Pedro A. Pérez–Mancera, Birgit Nimmervoll, Adil Jaulim, Hung‐Chang Chen, Dominick J. O. McIntyre, Rebecca Brais, Thomas C. Ricketts, Simon Pacey, Maike de la Roche, Richard J. Gilbertson, David C. Rubinsztein, Masashi Narita	2018	28
17	Expansion Phase 1 Study of Pegargiminase Plus Pemetrexed and Cisplatin in Patients With Argininosuccinate Synthetase 1–Deficient Mesothelioma: Safety, Efficacy, and Resistance Mechanisms JTO Clinical and Research Reports ·Peter W. Szlosarek, Melissa Phillips, Iuliia Pavlyk, Jeremy Steele, Jonathan Shamash, James Spicer, Sanjeev Kumar, Simon Pacey, Xiaoxing Feng, Amanda Johnston, John S. Bomalaski, Graeme Moir, Kelvin Lau, Stephen Ellis, Michael Sheaff	2020	23
18	Use of Pharmacokinetic/Pharmacodynamic Biomarkers to Support Rational Cancer Drug Development Biomarkers in Medicine ·Debashis Sarker, Simon Pacey, Paul Workman	2007	22
19	Results of a phase 1 clinical trial investigating a combination of the oral mTOR-inhibitor Everolimus (E, RAD001) and Gemcitabine (GEM) in patients (pts) with advanced cancers Journal of Clinical Oncology ·Simon Pacey, Daniel Rea, Neil Steven, C. Brock, Nicholas Knowlton, N. Shand, Katharine Hazell, Ulrike Zoellner, Anne O’Donnell, Ian Judson	2004	20
20	A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours Annals of Oncology ·Alastair Greystoke, Sarah P. Blagden, Anne Thomas, Edwina N. Scott, Gerhardt Attard, R. Molife, Laura Vidal, Simon Pacey, D Sarkar, A. Jenner, Johann S. de Bono, William P. Steward	2006	19

About Simon Pacey

Simon Pacey is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Biotechnology and Toxicology, having authored 69 papers that have together received 3.9k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (12 papers), Heat shock proteins research (11 papers), Cancer Genomics and Diagnostics (7 papers), Cancer Research and Treatments (6 papers), Cancer Immunotherapy and Biomarkers (6 papers), Neuroblastoma Research and Treatments (6 papers), Computational Drug Discovery Methods (6 papers) and Cancer therapeutics and mechanisms (6 papers). The work is most often cited by research in Cancer Research (1.7k citations), Oncology (1.3k citations), Pulmonary and Respiratory Medicine (1.1k citations), Molecular Biology (2.2k citations) and Pathology and Forensic Medicine (448 citations). Simon Pacey has collaborated with scholars based in United Kingdom, United States and France. Frequent co-authors include Javier García-Corbacho, Richard D. Baird, Florent Moulière, Nitzan Rosenfeld, James D. Brenton, Carlos Caldas, Jonathan C. M. Wan, Charles Massie, Chee-Seng Tan and David Gilligan. Their work appears in journals such as Journal of Clinical Oncology, Clinical Cancer Research, Annals of Oncology, Molecular Cancer Therapeutics and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact